Pipeline

We are developing differentiated peptide candidates to address unmet medical needs across therapeutic areas.

 
PARTNERS
PRECLINICAL
PHASE 1
PHASE 2
PHASE 3
REGISTRATION
Obesity
PROGRAM Petrelintide
Phase 2
PROGRAM Dapiglutide
Phase 1
PROGRAM Survodutide
PARTNERS 300X180 Logo Boehringer
Phase 3
PROGRAM ZP6590
Preclinical
Congenital Hyperinsulinism
Short Bowel Syndrome
PROGRAM Glepaglutide
Registration
Chronic inflammation
PROGRAM ZP9830
Phase 1
PROGRAM ZP10068
Preclinical

Latest scientific publications

All Scientific publications
  • Obesity Week

    Safety, Tolerability, and Clinical Effects of Petrelintide (ZP8396), A Long-acting Amylin Analog

  • ADA Scientific Sessions

    Dapiglutide is a dual agonist on human GLP-1- and GLP-2-receptors with a biased and prolonged signaling profile at the GLP-1R

  • ADA Scientific Sessions

    Petrelintide (ZP8396) selectively reduces intake of high fat diet in DIO rats

  • ADA Scientific Sessions

    Petrelintide (ZP8396) significantly reduces fat mass while preserving lean mass in DIO rats

We are targeting a number of important therapeutic areas of high unmet need with our robust pipeline of differentiated candidates.

David Kendall

Chief Medical Officer, Zealand Pharma

David ALR0987